Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2015-10-22 AGM Information
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting/Proxy Form 19 pages 90.4KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' for Phylogica Limited, dated 2015. It includes details about the time and place of the AGM, voting procedures, proxy instructions, and the agenda for the meeting. The agenda includes receipt and consideration of the annual financial report, adoption of the remuneration report, approval of placement capacity, and re-election of directors. The document also contains an explanatory statement related to the resolutions to be voted on at the AGM. This type of document is a notice sent to shareholders to inform them about the AGM and the matters to be discussed and voted on. It is not the annual report itself, nor is it a voting results announcement or proxy solicitation material. It is a presentation of materials shared for the AGM, including the agenda and explanatory notes. Therefore, the document fits the category of AGM Information (AGM-R). The document length (15,000 characters) and content confirm it is a full notice and explanatory statement for the AGM, not just a brief announcement or a report publication announcement.
2015-10-22 English
Chairman Appointment 2 pages 28.4KB
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Chairman of the board at Phylogica Ltd. It details the outgoing chairman's new role and the background of the new chairman. There is no financial data, no mention of a report or filing, and no regulatory or voting results. The content focuses on management changes at the board level. Therefore, the document fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and is a straightforward announcement, not a report or presentation.
2015-10-07 English
Annual General Meeting Date 1 page 20.7KB
AGM Information Classification · 95% confidence The document is a short announcement dated 7th October 2015 from Phylogica Ltd regarding the date and time of its upcoming Annual General Meeting (AGM) scheduled for 25th November 2015. It does not contain any financial data, detailed presentations, or reports but simply informs shareholders about the AGM date. The document length is only 557 characters, indicating it is a brief notice rather than a full report or presentation. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the AGM, specifically announcements about the meeting itself.
2015-10-06 English
Shareholder Newsletter 2 pages 154.2KB
Capital/Financing Update Classification · 95% confidence The document is a letter from the CEO dated October 2015, discussing a $10 million capital raise, strategic priorities, drug development progress, and collaboration milestones. It focuses on business updates, development strategy, and upcoming milestones rather than presenting detailed financial statements or comprehensive financial performance data. The content is consistent with a capital or financing update, highlighting the successful rights issue and its impact on the company's development program. There is no indication of it being an annual or interim report, earnings release, or regulatory filing. The length (6441 characters) and content suggest it is a detailed update rather than a brief announcement or a full financial report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2015-09-30 English
Full Year Statutory Accounts 48 pages 372.1KB
Annual Report Classification · 100% confidence The document is titled 'Annual Financial Statements 30 June 2015' and includes detailed sections such as Directors' Report, Auditor's Independence Declaration, Statement of Comprehensive Income, Statement of Financial Position, Statement of Cash Flows, Statement of Changes in Equity, Notes to the Financial Statements, Directors' Declaration, and Independent Auditor's Report. It covers the full fiscal year ended 30 June 2015 and contains comprehensive financial data, operating results, and detailed management discussion. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. These characteristics align with an Annual Report (10-K equivalent) filing, which is the official yearly report covering company activity and full financial performance.
2015-09-28 English
Preliminary Final Report 9 pages 100.8KB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary final report Year ended 30 June 2015' and contains detailed consolidated financial statements including the statement of comprehensive income, statement of financial position, statement of cash flows, and statement of changes in equity for the fiscal year ended 30 June 2015. It includes notes to the financial statements with detailed financial data such as revenues, expenses, assets, liabilities, equity, and cash flows. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of comprehensive financial data and notes confirms this is a full annual financial report. Appendix 4E is an Australian Securities Exchange (ASX) form used for preliminary final reports, which are essentially annual reports or annual financial statements. Therefore, this document should be classified as an Annual Report (10-K equivalent). FY 2015
2015-08-31 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.